|Bid||0.00 x 3100|
|Ask||0.00 x 900|
|Day's Range||45.16 - 48.96|
|52 Week Range||2.14 - 52.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.90|
Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced that it has increased its 2018 sales guidance to $150 million to $158 million, from $140 million to $148 million, following continued strong domestic sales in the third quarter and the recent launch of the t:slim X2™ Insulin Pump in select international markets. Sales, training and customer service outside of the United States are being provided by regional distribution partners, except in Canada. The t:slim X2 Insulin Pump is currently under review by Health Canada.
Tandem Diabetes Care (TNDM) needs investors to pay close attention to the stock based on moves in the options market lately.
Today, Tandem Diabetes Care (TNDM) stock continued the declining trend it began on September 14. Baird downgraded the stock recommendation from “buy” to “neutral.” On September 14, TNDM stock registered a decline of ~6.7% in pre-market trading and the stock was down ~7% during the day. None of the analysts recommend a “buy” for Tandem Diabetes Care.
Without pause, Tandem Diabetes Care Inc (NASDAQ: TNDM ) has surged 1,915 percent year-to-date. One sell-side analyst said Friday that the medical device manufacturer's valuation has peaked. The Rating ...
NEW YORK, NY / ACCESSWIRE / September 13, 2018 / U.S. markets were mixed on Wednesday as technology shares declined, dragging the Nasdaq into the red. The Dow Jones Industrial Average climbed 0.11 percent ...
Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced it will host an Institutional Investor and Analyst Day from 8:30am to 1:00pm Pacific Time on Tuesday, September 25, 2018 in San Diego, California. The program will include presentations regarding the Company’s longer-term vision, product pipeline, and international expansion. In addition, presentations will be given by clinical and industry experts on the subject of automated insulin delivery (AID).
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) continues to float higher, even without any major news. The market easily absorbed the company’s $100 million equity offering which was underwritten in August 2018. Not only are those who bought that offering at $28.50 in the green, but longtime investors in TNDM stock believe that sales of Tandem’s new insulin pump in the United States will justify the stock’s strong run-up.Source: Apple
Tandem Diabetes Care (TNDM) has been one of the best-performing medical device companies in 2018 and has already reported a YoY (year-over-year) rise of 1,814.4% YTD (year-to-date). To know more about Tandem Diabetes Care, be sure to read Tandem Diabetes Care Continues Its Strong Performance in Q2 2018. On June 21, the FDA approved Tandem Diabetes Care’s t:slim X2 insulin pump with Basal-IQ technology, an automated insulin delivery system that can help reduce the frequency of hypoglycemic events in diabetes patients.
Two years ago, Tandem Diabetes Care Inc.’s stock plummeted after a key health insurer favored a rival device, investors fretted about growing competition and analysts wrung their hands over the balance sheet. Tandem’s market value has ballooned to more than $2.5 billion from $26 million just this year in what Chief Financial Officer Leigh Vosseller describes as an “almost a rebirth” following the “roller-coaster ride” that was the past two years. Bullish Wall Street analysts have played leap-frog in a race to slap ever-higher price targets on the stock: the current high stands at $60 a share, compared with Thursday’s $44.22 closing price.
Tandem Diabetes Care (TNDM) has had a stellar 2018 so far. The stock has registered eye-watering gains of 1,700% year-to-date. Over the last month, the stock is up ~77%.
NEW YORK, NY / ACCESSWIRE / August 31, 2018 / Wall Street retreated from records on Thursday, on news that U.S. President Donald Trump wants to move ahead with his plan to slap tariffs on $200 billion ...
Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring integration, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Baird 2018 Global Healthcare Conference in New York, NY. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section. Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience.
NEW YORK, NY / ACCESSWIRE / August 28, 2018 / U.S. markets rose Monday, with the S&P 500 and Nasdaq finishing at new records for the second consecutive session, on news of the new trade agreement with ...
Medical device maker Tandem Diabetes Care Inc (NASDAQ: TNDM ) has high growth potential, but its upside could be limited by valuation, according to Bank of America Merrill Lynch. The Analyst Analyst Travis ...
Investors need to pay close attention Tandem Diabetes (TNDM) stock based on the movements in the options market lately.
Investors recently long EKSO have made 65% with more potential upside to come. Tandem Diabetes Care, Inc. (TNDM) has traded from $2 to $34/share this year, a gain of over 1700%. This is based on improving commercial success with their diabetes business and another FDA approval in the summer.
Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced its launch of the t:slim X2™ Insulin Pump with Basal-IQ™ Technology, a predictive low glucose suspend (PLGS) feature designed to help reduce the frequency and duration of low glucose events (hypoglycemia). It is integrated with the Dexcom G6® CGM System, which requires no fingersticks for calibration or diabetes treatment decisions.1,2 The Company has begun sending emails with update instructions to all in-warranty t:slim X2 users in the United States, who have the option to add the new feature free of charge via remote software update.3 t:slim X2 Pumps pre-loaded with Basal-IQ Technology are expected to begin shipping to new customers by the end of August.
When it comes to investing, it’s definitely smart to focus on high-quality companies. But this does not mean you should avoid more speculative plays. Low-price, cheap stocks can represent tremendous opportunities.
From $8.80 on May 8, Tandem Diabetes Care’s (TNDM) stock price steadily rose to a high of $33.44 on August 3. It recovered after that to its current level of $30.75.
Additionally, Tandem commenced enrollment in the US portion of the International Diabetes closed Loop trial in June. Tandem is developing a next-generation hardware platform, t:sport Insulin Delivery System, which is expected to be half the size of the t:slim pump.
Tandem Diabetes Care’s (TNDM) interest expenses increased from $2.89 million in the second quarter of 2017 to $3.11 million in the second quarter. Its net other expense jumped from $2.83 million in the second quarter of 2017 to $45.36 million in the second quarter primarily due to a revaluation loss of $42.55 million in the fair value of Tandem’s Series A and Series B stock warrants.
Tandem Diabetes Care (TNDM) generated revenues of ~$34.13 million in the second quarter, which it reported on July 30. It reported revenues of $21.33 million in the second quarter of 2017.